- Home
- ESPR vs ORN Comparison
ESPR vs ORN Comparison
Compare ESPR & ORN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- ORN
- Stock Information
- Founded
- ESPR 2008
- ORN 1994
- Country
- ESPR United States
- ORN United States
- Employees
- ESPR N/A
- ORN N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- ORN Military/Government/Technical
- Sector
- ESPR Health Care
- ORN Industrials
- Exchange
- ESPR Nasdaq
- ORN Nasdaq
- Market Cap
- ESPR 305.0M
- ORN N/A
- IPO Year
- ESPR 2013
- ORN 2007
- Fundamental
- Price
- ESPR $0.89
- ORN $7.72
- Analyst Decision
- ESPR Buy
- ORN Strong Buy
- Analyst Count
- ESPR 7
- ORN 3
- Target Price
- ESPR $5.93
- ORN $12.50
- AVG Volume (30 Days)
- ESPR 5.7M
- ORN 395.2K
- Earning Date
- ESPR 05-06-2025
- ORN 04-29-2025
- Dividend Yield
- ESPR N/A
- ORN N/A
- EPS Growth
- ESPR N/A
- ORN N/A
- EPS
- ESPR N/A
- ORN 0.08
- Revenue
- ESPR $259,574,000.00
- ORN $824,375,000.00
- Revenue This Year
- ESPR $5.70
- ORN $3.55
- Revenue Next Year
- ESPR N/A
- ORN $11.66
- P/E Ratio
- ESPR N/A
- ORN $97.47
- Revenue Growth
- ESPR 12.99
- ORN 15.58
- 52 Week Low
- ESPR $0.82
- ORN $4.64
- 52 Week High
- ESPR $3.94
- ORN $12.12
- Technical
- Relative Strength Index (RSI)
- ESPR 36.95
- ORN 78.32
- Support Level
- ESPR $0.93
- ORN $6.30
- Resistance Level
- ESPR $1.11
- ORN $7.08
- Average True Range (ATR)
- ESPR 0.10
- ORN 0.40
- MACD
- ESPR 0.02
- ORN 0.19
- Stochastic Oscillator
- ESPR 25.10
- ORN 89.87
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.